Literature DB >> 12874299

Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan.

Junji Uehori1, Misako Matsumoto, Shoutaro Tsuji, Takashi Akazawa, Osamu Takeuchi, Shizuo Akira, Tsutomu Kawata, Ichiro Azuma, Kumao Toyoshima, Tsukasa Seya.   

Abstract

The Mycobacterium bovis bacillus Calmette-Guérin (BCG) cell wall skeleton (CWS) consists of mycolic acids, arabinogalactan, and peptidoglycan (PGN) and activates Toll-like receptor 2 (TLR2) and TLR4. Here we investigated the ability of the essential portion of highly purified BCG CWS to support the TLR agonist function by using the following criteria: myeloid dendritic cell (DC) maturation, i.e., tumor necrosis factor alpha (TNF-alpha) production and CD83/CD86 up-regulation. The purified PGN region was sufficient to activate TLR2 and TLR4 in mouse DCs and macrophages; in TLR2 and TLR4 double-knockout cells the BCG PGN-mediated TNF-alpha production ability was completely impaired. Likewise, stimulation with BCG CWS of HEK293 cells expressing either human TLR2 or TLR4, MD-2, and CD14 resulted in NF-kappa B activation as determined by a reporter assay. Notably, specific blockers of extracellular human TLR2 (an original cocktail of monoclonal antibodies TLR2.45 and TH2.1) and TLR4 (E5531) inhibited BCG CWS-mediated NF-kappa B activation by 80%. Using this human TLR blocking system, we tested whether human myeloid DC maturation was TLR2 and TLR4 dependent. BCG PGN-mediated DC maturation was blocked by 70% by suppression of both TLR2 and TLR4 and by 30 to 40% by suppression of either of these TLRs. Similar but less profound suppression of BCG CWS-mediated DC maturation was observed. Hence, the presence of BCG PGN is a minimal requirement for activation of both TLR2 and TLR4 in human DCs, unlike the presence of PGNs of gram-positive bacteria, which activate only TLR2. Unexpectedly, however, BCG PGN, unlike BCG CWS, barely activated NF-kappa B in HEK293 cells coexpressing TLR2 plus TLR1, TLR2 plus TLR4, TLR2 plus TLR6, or TLR2 plus TLR10, suggesting that PGN receptors other than TLR2 and TLR4 present on human DCs but not on HEK293 cells are involved in TLR signaling for DC activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874299      PMCID: PMC165983          DOI: 10.1128/IAI.71.8.4238-4249.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors.

Authors:  A Ozinsky; D M Underhill; J D Fontenot; A M Hajjar; K D Smith; C B Wilson; L Schroeder; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide.

Authors:  T H Flo; O Halaas; E Lien; L Ryan; G Teti; D T Golenbock; A Sundan; T Espevik
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

4.  Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall.

Authors:  S Tsuji; J Uehori; M Matsumoto; Y Suzuki; A Matsuhisa; K Toyoshima; T Seya
Journal:  J Biol Chem       Date:  2001-04-19       Impact factor: 5.157

5.  Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses.

Authors:  T K Means; B W Jones; A B Schromm; B A Shurtleff; J A Smith; J Keane; D T Golenbock; S N Vogel; M J Fenton
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

6.  MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components.

Authors:  R Dziarski; Q Wang; K Miyake; C J Kirschning; D Gupta
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

7.  Endotoxin-induced maturation of MyD88-deficient dendritic cells.

Authors:  T Kaisho; O Takeuchi; T Kawai; K Hoshino; S Akira
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

8.  Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46.

Authors:  M Kurita-Taniguchi; A Fukui; K Hazeki; A Hirano; S Tsuji; M Matsumoto; M Watanabe; S Ueda; T Seya
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

9.  A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway.

Authors:  E Lien; J C Chow; L D Hawkins; P D McGuinness; K Miyake; T Espevik; F Gusovsky; D T Golenbock
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

10.  Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions.

Authors:  M Nishiguchi; M Matsumoto; T Takao; M Hoshino; Y Shimonishi; S Tsuji; N A Begum; O Takeuchi; S Akira; K Toyoshima; T Seya
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

View more
  61 in total

1.  Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages.

Authors:  Nasim A Begum; Kazuo Ishii; Mitsue Kurita-Taniguchi; Masako Tanabe; Mika Kobayashi; Yasuhiro Moriwaki; Misako Matsumoto; Yasuo Fukumori; Ichiro Azuma; Kumao Toyoshima; Tsukasa Seya
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 2.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae.

Authors:  Katherine S Lee; Charles A Scanga; Eric M Bachelder; Quanyi Chen; Clifford M Snapper
Journal:  Cell Immunol       Date:  2007-05-22       Impact factor: 4.868

Review 4.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

6.  Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion.

Authors:  Lilly Y W Bourguignon; Gabriel Wong; Christine A Earle; Weiliang Xia
Journal:  Cytoskeleton (Hoboken)       Date:  2011-11-29

7.  Polyarginine induces an antitumor immune response through binding to toll-like receptor 4.

Authors:  Yong Yang; Joy Wolfram; Xiaohong Fang; Haifa Shen; Mauro Ferrari
Journal:  Small       Date:  2013-12-10       Impact factor: 13.281

8.  Expression of toll-like receptor 4 and MD-2 gene and protein in Kupffer cells after ischemia-reperfusion in rat liver graft.

Authors:  Yong Peng; Jian-Ping Gong; Chang-An Liu; Xu-Hong Li; Ling Gan; Shou-Bai Li
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

9.  Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study.

Authors:  Ken Kodama; Masahiko Higashiyama; Koji Takami; Kazuyuki Oda; Jiro Okami; Jun Maeda; Takashi Akazawa; Misako Matsumoto; Tsukasa Seya; Mariko Wada; Kumao Toyoshima
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

Review 10.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.